Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05747534 · ClinicalTrials.gov registry record · Phase 2

AT1001 for the Treatment of Long COVID

A Phase 2 study of Long COVID and Post-Acute COVID-19 Syndrome, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
2
Study locations

NCT05747534: Recruiting Phase 2 study of Long COVID and Post-Acute COVID-19 Syndrome, sponsored by Massachusetts General Hospital.

NCT05747534 is a Phase 2 study of Long COVID and Post-Acute COVID-19 Syndrome that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 150 participants, below the 2,185-participant average among 50 other Long COVID trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05747534, a Phase 2 study of Long COVID and Post-Acute COVID-19 Syndrome, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orally four times a day (QID) for 21 days.

Conditions Studied

Long COVID Post-Acute COVID-19 Syndrome Long COVID-19 Post Acute Sequelae of COVID-19

Interventions

  • DRUG Placebo
  • DRUG Larazotide Acetate

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-05-31
Est. Completion 2027-03-31
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05747534

The ClinicalTrials.gov registry entry for NCT05747534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,185-participant average among 50 other Long COVID trials with a reported enrollment target (93% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05747534 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05747534 about?

NCT05747534 is a clinical study titled "AT1001 for the Treatment of Long COVID". The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orall...

What is the current status of trial NCT05747534?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-05-31. Estimated completion is 2027-03-31.

What conditions does trial NCT05747534 study?

This clinical trial studies the following conditions: Long COVID, Post-Acute COVID-19 Syndrome, Long COVID-19, Post Acute Sequelae of COVID-19.

What interventions are being tested in trial NCT05747534?

The interventions under investigation include: Placebo (DRUG), Larazotide Acetate (DRUG).

Who is sponsoring clinical trial NCT05747534?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05747534 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

Post-Acute COVID-19 Syndrome

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.